Magnesium sulphate at 30 to 34 weeks’ gestational age: neuroprotection trial (MAGENTA) - study protocol

BACKGROUND: Magnesium sulphate is currently recommended for neuroprotection of preterm infants for women at risk of preterm birth at less than 30 weeks’ gestation, based on high quality evidence of benefit. However there remains uncertainty as to whether these benefits apply at higher gestational ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Crowther, Caroline A, Middleton, Philippa F, Wilkinson, Dominic, Ashwood, Pat, Haslam, Ross
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636106/
https://www.ncbi.nlm.nih.gov/pubmed/23570677
http://dx.doi.org/10.1186/1471-2393-13-91

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636106/
https://www.ncbi.nlm.nih.gov/pubmed/23570677
http://dx.doi.org/10.1186/1471-2393-13-91

Ejemplares similares